This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duval, X.
Right arrow Articles by Vilde, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duval, X.
Right arrow Articles by Vilde, J.-L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 570-574, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.570-574.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

Xavier Duval,1* Claire Lamotte,2 Ester Race,3 Diane Descamps,4 Florence Damond,4 François Clavel,3 Catherine Leport,1 Gilles Peytavin,2 and Jean-Louis Vilde1

Service des Maladies Infectieuses et Tropicales,1 Service de Pharmacie Clinique,2 Laboratoire Viralliance, Hôpital Bichat Claude Bernard, Paris, France,3 Service de Virologie4

Received 30 May 2001/ Returned for modification 30 August 2001/ Accepted 1 November 2001

The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human immunodeficiency virus (HIV) infection. The mean minimal plasma APV concentrations in groups A and B were 58 and 1,320 ng/ml, respectively, corresponding to APV inhibitory quotients of 0.2 (range, 0.03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses.

* Corresponding author. Mailing address: Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75877 Paris, Cedex 18, France. Phone: 33 1 40 25 78 03. Fax: 33 1 40 25 88 60. E-mail: xavier.duval{at}bch.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, February 2002, p. 570-574, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.570-574.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Eron, J. J. Jr., Park, J.-G., Haubrich, R., Aweeka, F., Bastow, B., Pakes, G. E., Yu, S., Wu, H., Richman, D. D., for the ACTG5126 Study Team, (2009). Predictive Value of Pharmacokinetics-Adjusted Phenotypic Susceptibility on Response to Ritonavir-Enhanced Protease Inhibitors (PIs) in Human Immunodeficiency Virus-Infected Subjects Failing Prior PI Therapy. Antimicrob. Agents Chemother. 53: 2335-2341 [Abstract] [Full Text]  
  • Pellegrin, I., Breilh, D., Coureau, G., Boucher, S., Neau, D., Merel, P., Lacoste, D., Fleury, H., Saux, M.-C., Pellegrin, J.-L., Lazaro, E., Dabis, F., Thiebaut, R., for the ANRS Co3 Aquitaine Cohort, (2007). Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrob. Agents Chemother. 51: 1473-1480 [Abstract] [Full Text]  
  • Marcelin, A.-G., Lamotte, C., Delaugerre, C., Ktorza, N., Ait Mohand, H., Cacace, R., Bonmarchand, M., Wirden, M., Simon, A., Bossi, P., Bricaire, F., Costagliola, D., Katlama, C., Peytavin, G., Calvez, V. (2003). Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 47: 594-600 [Abstract] [Full Text]  
  • Piliero, P. J. (2003). Early Factors in Successful Anti-HIV Treatment. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 10-20 [Abstract]  
  • Hirsch, M. S. (2002). HIV Drug Resistance -- A Chink in the Armor. NEJM 347: 438-439 [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»